Dr. Ahmed Salem

Assistant Professor/ Radiation Oncology Consultant The Hashemite University

Young investigator Regional Track

Dr. Ahmed Salem is a consultant in Radiation Oncology based in Amman, Jordan. Clinically specializing in radiation oncology, Dr. Salem’s research focuses on lung cancer, radiation biology, novel trials, biomarkers and hypoxia.

Dr. Salem completed his training in radiation oncology at Jordan’s King Hussein Cancer Center in 2014, attaining fellowships and specialty certifications in clinical (FRCR) and radiation (ESTRO fellowship & Jordanian board). Dr. Salem also completed a Cancer Research UK (CRUK) funded clinical research fellowship in 2017, receiving his PhD from the University of Manchester for research focusing on non-invasive therapeutic lung cancer biomarkers. Dr. Salem attained specialist clinical oncology registration in the UK in 2017 and worked as a clinical oncology consultant in the Christie Hospital till January 2022. 

Dr. Salem has delivered world-leading clinical and translational cancer studies including a first-in-human study of a hypoxia biomarker quantified using a novel MRI technique and subgroup analyses of the world’s largest small-cell lung cancer radiotherapy trial. He has published over 63 papers in prestigious journals such as JAMA Oncology with research outputs attracting awards, invited editorials and expert discussions in eminent conferences, as well as being integrated into clinical practice guidelines (ESMO and ASTRO). Dr. Salem is a recipient of more than 10 prestigious academic oncology awards such as the ESTRO Accuray Award and the ASTRO International-US annual meeting scientific abstract award.

Apart from research, Dr. Salem is a keen educationalist. He is the current director of ESTRO FALCON lung cancer contouring workshops, a specialist examiner in the FRCR part 1 examination and supervisors a number of MSc and PhD students.   

Dr. Salem’s career goal is to lead an innovative radiotherapy research portfolio, aiming to deliver survival and quality-of-life improvements for cancer patients.